Endpoints News 生物医药· Elizabeth Cairns·· 16 天前AI 评分21
Novo 将推迟 CagriSema 在欧洲上市两年
Novo won't launch CagriSema in Europe for 'a couple of years,' CFO says
AI 导读
Novo 表示其肥胖症药物 CagriSema 在欧洲的上市将推迟两年,公司需在欧洲进行新的临床试验。
正文
Novo won’t launch its big obesity hope CagriSema in Europe for another “couple of years,” as it will have to conduct new trials at European …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news